Using controlled clinical trials to learn more about acute drug‐induced liver injury

Drug‐induced liver injury (DILI) is of major interest to hepatologists and clinicians in general, patients, government regulators, and the pharmaceutical industry. Understanding why this form of injury occurs only in certain individuals has major implications for the development and availability of drug therapies and in the prevention of these events. A single controlled clinical trial may be unlikely to show cases of such rare events, but in the aggregate, clinical trials offer a unique resource for learning more about individual susceptibility and developing truly predictive new biomarkers for DILI. We pose the question as to whether clinical trials could be modified or improved to provide data that would better answer some of the outstanding issues. At a recent (March 2008) public meeting, experts from academia, industry, and regulatory bodies discussed several major issues regarding liver safety in clinical trials including: what signals of liver injury should justify stopping administration of study drug or allowing it to continue; if deliberate rechallenge should be done and under what circumstances; whether patients with liver disease should be included in clinical trials; and what kinds of new biomarkers will be needed to answer these questions more clearly. Past clinical trials have not provided data to settle those issues, and reliance has defaulted to consensus of expert opinions. Modified and better clinical trials with standardized collection of data and biospecimens are probably the best source of new and potentially valuable information to supplant current rules based on consensus of expert opinions and to understand by what mechanisms and how to distinguish those individuals who are susceptible to severe DILI. (HEPATOLOGY 2008.)

[1]  R. Hultcrantz,et al.  Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. , 2007, Journal of hepatology.

[2]  U. Andersson,et al.  Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies. , 2007, Archives of biochemistry and biophysics.

[3]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver disease. , 1995, Gastroenterology clinics of North America.

[4]  Leonard J. Seligman.  Industry Perspectives , 1997, SIGMOD Rec..

[5]  J. Senior,et al.  Troglitazone-induced liver failure: a case study. , 2003, The American journal of medicine.

[6]  P. Kamath.  The need for better clinical trials , 2008, Hepatology.

[7]  A. Albanese,et al.  Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. , 1998, American journal of respiratory and critical care medicine.

[8]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[9]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[10]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[11]  M. Bonacini.  Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  H. Zimmerman.  The Spectrum of Hepatotoxicity , 2015, Perspectives in biology and medicine.

[13]  A. García-Sánchez,et al.  Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. , 1995, Gastroenterology.

[14]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[15]  Programmierbarer Thermoblock,et al.  From industry , 1991 .

[16]  G. Aithal.  Dangerous liaisons: drug, host and the environment. , 2007, Journal of hepatology.

[17]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[18]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[19]  P. Watkins.  Insight into hepatotoxicity: The troglitazone experience , 2005, Hepatology.

[20]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[21]  D. Altshuler,et al.  Harvesting Medical Information from the Human Family Tree , 2005, Science.

[22]  L. Seeff.  Guidelines for detection of hepatotoxicity due to drugs and chemicals , 1980 .

[23]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[24]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[25]  A. Karmen.  A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum. , 1955, The Journal of clinical investigation.

[26]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[27]  Herrine,et al.  Schiff's diseases of the liver , 1999, Gastroenterology.

[28]  A. McCullough,et al.  Alcoholic Liver Disease , 2010, The American Journal of Gastroenterology.

[29]  Luis Rodrigo,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[30]  J. Snawder,et al.  Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen‐induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injury , 1999, Hepatology.

[31]  A. Karmen,et al.  Transaminase activity in human blood. , 1955, The Journal of clinical investigation.

[32]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[33]  H. El‐Serag,et al.  Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. , 2005, Journal of hepatology.

[34]  H. Goto,et al.  The fluctuations of viral load and serum alanine aminotransferase levels in chronic hepatitis C. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[35]  J. Ambroso,et al.  Lymphocyte loss and immunosuppression following acetaminophen-induced hepatotoxicity in mice as a potential mechanism of tolerance. , 2007, Chemical research in toxicology.

[36]  R. Fontana,et al.  Drug-Induced Liver Injury Network (DILIN) Prospective Study , 2009, Drug safety.

[37]  C. Hsiung,et al.  A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.

[38]  Geoffrey B. Nilsen,et al.  Whole-Genome Patterns of Common DNA Variation in Three Human Populations , 2005, Science.

[39]  A D Roses,et al.  Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) , 2007, The Pharmacogenomics Journal.

[40]  M. Yuen,et al.  Antituberculosis drug‐related liver dysfunction in chronic hepatitis B infection , 2000, Hepatology.

[41]  U. Thorgeirsson,et al.  Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. , 1975, Chest.

[42]  H. Margolis,et al.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. , 1999, American journal of public health.

[43]  K. Lindor,et al.  Nonalcoholic fatty liver disease. , 2007, Annals of epidemiology.

[44]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[45]  C. Klaassen,et al.  Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[47]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[48]  U. Veronesi,et al.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial , 2005, BMJ : British Medical Journal.

[49]  S. Goldberg,et al.  Hepatotoxicity Associated with Isoniazid Preventive Therapy: A 7-Year Survey from a Public Health Tuberculosis Clinic , 2000 .

[50]  E. Björnsson,et al.  Outcome and prognostic markers in severe drug‐induced liver disease , 2005, Hepatology.